

Add Logo

EHR: select (Add company name) from your EHR!

CROHN'S/ UC REFERRAL FORM

Fax: (000) 000-0000
Phone: (000) 000-0000

PATIENT INFORMATION

Patient's Name:		SSN:		DOB:	
Address:		City:		State:	Zip:
Home Phone:	Cell:	Height:	Weight:		Gender: Male Female
Email		Diagnosis Code:			

INSURANCE INFORMATION (or attach copy of the cards)

Primary Insurance:	Policy Holder:	Relationship:	Policy #:	Group #:
Secondary Insurance:	Policy Holder:	Relationship:	Policy #:	Group #:

PRESCRIPTION INFORMATION (for IV medication attach a copy of the prescription)

AMJEVITA™ (adalimumab-atto)

SureClick 40 mg/0.8 mL Prefilled Syringe 20 mg/0.4 mL Prefilled Syringe 40 mg/0.8 mL

Induction: 160 mg SubQ Day 1

4 x 40 mg SubQ in one day

2 x 40 mg SubQ per day for two consecutive days

2 x 40 mg SubQ Day 15

Qty: 6

Refills: 0

Maintenance:

40 mg SubQ every other week

Qty:

Refills:

CIMZIA® (certolizumab pegol)

Prefilled Syringe Lyophilized Powder

Induction: 400 mg (2 x 200 mg) SubQ weeks 0, 2, 4

Qty: 28 day supply

Refills: 0

Maintenance:

2 x 200 mg SubQ every 4 weeks

2 x 200 mg SubQ every 2 weeks

200 mg SubQ every 2 weeks

Qty: 28 day supply

Refills:

DUPIXENT® (dupilumab)

Prefilled Syringe Pen

Induction: Inject 2 x 300 mg (600 mg) SubQ Day 1

Qty: 2 for 14 days

Refills: None

Maintenance: Inject 300 mg SubQ every other week

Qty: 2 for 28 days

Refills:

Entocort® (budesonide)

3 mg capsules

9 mg PO daily

Qty: 90

Refills:

HUMIRA® (adalimumab)

Pen Prefilled Syringe

Citrate Free (CF) Original Formula

Induction:

160 mg SubQ day 1, 80 mg SubQ day 15

80 mg SubQ day 1, 80 mg SubQ day 2/ 80 mg SubQ day 15

Qty: 1 pack

Refills: 0

Maintenance:

40 mg SubQ every other week

Qty: 28 day supply

Refills:

** If dosage form is not selected, PENS will be dispensed.**

RINVOQ® (upadacitinib) extended-release tablets

15 mg 30 mg 45 mg

Induction:

45 mg PO once daily for 8 weeks 45 mg PO once daily for 12 weeks

Qty: 2 bottles

Refills: 0

Maintenance: _____ mg once daily

Qty:

Refills:

IMMUNOSUPPRESSIVE INFUSION Biosimilar authorized

AVSOLA®

ENTYVIO®

INFLECTRA®

Infliximab

REMICADE®

RENFLEXIS®

Initial Dose: _____ mg/kg at week 0, 2, and 6 Maintenance Dose: _____ mg/kg every 8 weeks

Other: _____ mg/kg every _____ weeks

Refills: _____

OTHER

STRENGTH:

SIG/DIRECTIONS:

REFILLS:

QUANTITY:

As required by your state, Prescriber to check "Dispense as written" or handwritten "Brand Medically Necessary" and sign to prevent generic substitution.

Dispense as written

PHYSICIAN INFORMATION

Injection Training: Office to Instruct SP to Arrange Teaching

Prescriber Name:		Phone:		Fax:	
Office Contact:		Email:			
Address:		Ship To: <input type="checkbox"/> Patient <input type="checkbox"/> MD Office			
NPI #:		Tax ID#:			
Prescription Signature:				Date:	